> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Committee Backs Moderna Flu Vaccine
- URL: https://www.fdaweb.com/committee-backs-moderna-flu-vaccine/
- Published: 2026-06-18T12:00:00.000Z
- Updated: 2026-09-14T13:41:29.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5161332

The FDA Vaccines and Related Biologic Products Advisory Committee has voted to recommend approval of Moderna’s mFlusiva mRNA flu shot. The Associated Press [reports](https://kdhnews.com/news/science/fda-panel-backs-first-of-its-kind-flu-vaccine-using-mrna-technology/?ref=fdaweb.com) the company is seeking approval for the vaccine’s use in people ages 50-64, along with authorization for use in those aged 65 and older, while Moderna conducts additional testing.

In advance of the advisory committee meeting, FDA reviewers had issued a [briefing document](https://www.fdaweb.com/panel-to-weigh-favorable-data-on-modernas-mrna-flu-vaccine/) with a more positive outlook on the vaccine than many observers had expected. The agency had issued a February Refusal-to-File letter attributed to concerns that the company’s Phase 3 trial used an inadequate control group to demonstrate efficacy.